SIREN : 430061820
FDA PATRIMOINE is a French company founded 26 years ago, specialized in the sector Gestion de fonds. Based in CHAMBERY (73000), this company of category PME shows in 2021 a revenue of 182 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2021 | 2020 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 182 354 € | 176 783 € | 174 128 € | 174 061 € | 171 837 € |
| Net income | 32 209 € | 34 480 € | 23 642 € | 22 517 € | 16 546 € |
| EBITDA | 48 572 € | 52 012 € | 37 550 € | 29 629 € | 28 534 € |
| Net margin | 17.7% | 19.5% | 13.6% | 12.9% | 9.6% |
In 2021, FDA PATRIMOINE achieves revenue of 182 k€. Revenue is growing positively over 5 years (CAGR: +1.2%). Vs 2020: +3%. After deducting consumption (0 €), gross margin stands at 182 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 49 k€, representing 26.6% of revenue. Warning negative scissor effect: despite revenue change (+3%), EBITDA varies by -7%, reducing margin by 2.8 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 32 k€, i.e. 17.7% of revenue. This profit can be retained or distributed to shareholders.
182 354 €
182 354 €
48 572 €
40 543 €
32 209 €
26.6%
The debt ratio (= Financial debt / Equity x 100) stands at 47%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 64%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.1 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 22.1% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
47.11%
63.906%
22.068%
3.118
0.9%
In 2021, the debt ratio of FDA PATRIMOINE (47.11) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2021, the financial autonomy of FDA PATRIMOINE (63.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2021, the repayment capacity of FDA PATRIMOINE (3.12) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 125.35. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.3x. Coverage is limited: any activity downturn would jeopardize interest payments.
125.353
1.346
In 2021, the liquidity ratio of FDA PATRIMOINE (125.35) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2021, the interest coverage of FDA PATRIMOINE (1.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 42 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 23 days. The company must finance 19 days of gap between collections and payments. Overall, WCR represents 15 days of revenue, i.e. 7 k€ to permanently finance. Notable WCR improvement over the period (-72%), freeing up cash.
7 498 €
42 j
23 j
0 j
15 j
Based on 76 transactions of similar company sales
in 2021,
the value of FDA PATRIMOINE is estimated at
158 702 €
(range 57 909€ - 325 475€).
With an EBITDA of 48 572€, the sector multiple of 2.9x is applied.
The price/revenue ratio is 0.33x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 76 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare FDA PATRIMOINE with other companies in the same sector:
The revenue of FDA PATRIMOINE in 2021 is 182 k€.
Yes, FDA PATRIMOINE generated a net profit of 32 k€ in 2021.
The headquarters of FDA PATRIMOINE is located in CHAMBERY (73000), in the department Savoie.
The tax return of FDA PATRIMOINE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
FDA PATRIMOINE operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.